Form 4: Cidara Director's Options Cashed Out in Merck Merger

Director James Merson's stock options in Cidara Therapeutics were converted to cash following the company's acquisition by Merck on January 7, 2026.

Summary

• A Merger Agreement was executed on November 13, 2025, between Cidara Therapeutics, Inc., Merck Sharp & Dohme LLC, and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck.
• On January 7, 2026, Caymus Purchaser, Inc. completed a tender offer to acquire all outstanding common stock and Series A Convertible Voting Preferred Stock of Cidara Therapeutics, Inc.
• Following the tender offer, Cidara Therapeutics, Inc. merged with and into Caymus Purchaser, Inc., with Cidara continuing as the surviving corporation and a wholly owned subsidiary of Merck.
• Director James Merson's outstanding stock options became fully vested and exercisable immediately prior to and contingent upon the effective time of the Merger.
• Unexercised options were cancelled at the effective time of the Merger and converted into a cash payment.
• The cash payment was calculated as the product of the total number of common shares subject to the option multiplied by the excess of $221.50 per common share over the option's exercise price.
• Options with exercise prices of $12.63 (4,250 shares), $12.64 (2,125 shares), and $21.31 (11,100 shares) were reported as disposed of, totaling 17,475 shares.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of a merger where Cidara Therapeutics, Inc. was acquired by Merck, leading to the cash-out of director's stock options at a significant premium. This is a very positive outcome for the company's shareholders and option holders.

Positives

• Director Merson's stock options were fully vested and converted to cash, indicating a successful exit for option holders.
• The merger price of $221.50 per common share represents a significant premium over the reported option exercise prices of $12.63, $12.64, and $21.31.

Negatives

• Cidara Therapeutics, Inc. ceased to be an independent publicly traded entity, becoming a wholly owned subsidiary of Merck.

Future Outlook

The filing primarily reports the completion of a merger and the subsequent disposition of insider stock options. It does not contain forward-looking statements regarding Cidara Therapeutics, Inc.'s future as an independent entity, as it is now a wholly owned subsidiary of Merck.

Industry Context

This acquisition by Merck of Cidara Therapeutics, Inc. aligns with the ongoing trend of consolidation in the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire smaller biotech firms to expand their pipelines and intellectual property portfolios.

Comparison to Industry Standards

• The acquisition price of $221.50 per share for Cidara Therapeutics, Inc. common stock, resulting in significant cash-out value for options with low exercise prices, suggests a favorable valuation for Cidara shareholders and option holders compared to typical biotech acquisitions.
• Merck's acquisition of Cidara Therapeutics, Inc. is consistent with strategic moves by major pharmaceutical companies like Pfizer acquiring Seagen for $43 billion or AbbVie acquiring ImmunoGen for $10.1 billion, aiming to bolster specific therapeutic areas or technology platforms.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $221.50 per common share for their stock as part of the tender offer.
• Option Holders (like Director Merson): Received cash for their vested options based on the merger price minus the exercise price.
• Employees: Cidara employees are now part of Merck, subject to Merck's employment policies and benefits.
• Customers/Suppliers: Cidara's products/services and supply chain are now integrated into Merck's operations.

Next Steps

• Cidara Therapeutics, Inc. will operate as a wholly owned subsidiary of Merck.
• Integration of Cidara's operations and assets into Merck's broader business structure.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Merck, Merger, Acquisition, Tender Offer, Stock Options, Form 4, Insider Transaction, James Merson, Biotechnology, Pharmaceuticals